Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

BACKGROUND: Erythropoietin (EPO) has been suggested to promote cardiac repair after MI. However, the randomized, double-blind, placebo controlled REVIVAL-3 trial showed that short term high dose EPO in timely reperfused myocardium does not improve left ventricular ejection fraction after 6 months. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Steppich, Birgit, Groha, Philip, Ibrahim, Tareq, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Hadamitzky, Martin, Kastrati, Adnan, Ott, Ilka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5251242/
https://www.ncbi.nlm.nih.gov/pubmed/28109258
http://dx.doi.org/10.1186/s12872-016-0464-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5251242/
https://www.ncbi.nlm.nih.gov/pubmed/28109258
http://dx.doi.org/10.1186/s12872-016-0464-3

Ejemplares similares